Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider James C. Hamilton Sells 611 Shares

Key Points

• Insider James C. Hamilton sold 611 shares of Arrowhead Pharmaceuticals at an average price of $20.00, decreasing his position by 0.22%.
• The company reported a quarterly earnings per share (EPS) of ($1.26), missing analysts’ expectations, with revenue of $27.77 million for the period.
• Analysts have a consensus rating of "Moderate Buy" for Arrowhead Pharmaceuticals, with a target price of $43.14, indicating potential upside from current levels.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James C. Hamilton sold 611 shares of the company's stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $20.00, for a total value of $12,220.00. Following the sale, the insider owned 271,511 shares of the company's stock, valued at approximately $5,430,220. This represents a 0.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock traded up $1.73 during midday trading on Friday, reaching $20.51. The stock had a trading volume of 5,200,816 shares, compared to its average volume of 1,944,591. The stock has a market cap of $2.84 billion, a PE ratio of -16.02, a P/E/G ratio of 76.81 and a beta of 0.94. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The firm has a fifty day simple moving average of $16.63 and a two-hundred day simple moving average of $15.94. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $27.34.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The company had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same period last year, the business earned ($1.38) EPS. As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday. Chardan Capital reiterated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Finally, Royal Bank Of Canada decreased their price objective on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a report on Friday, August 8th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.14.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. raised its stake in Arrowhead Pharmaceuticals by 2.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company's stock worth $714,000 after acquiring an additional 803 shares during the last quarter. Oak Ridge Investments LLC grew its position in Arrowhead Pharmaceuticals by 2.5% during the 1st quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company's stock worth $430,000 after purchasing an additional 823 shares during the period. Resona Asset Management Co. Ltd. grew its position in Arrowhead Pharmaceuticals by 8.7% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company's stock worth $180,000 after purchasing an additional 900 shares during the period. Empowered Funds LLC grew its position in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock worth $194,000 after purchasing an additional 979 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Arrowhead Pharmaceuticals by 9.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,476 shares of the biotechnology company's stock worth $184,000 after purchasing an additional 1,195 shares during the period. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.